199 related articles for article (PubMed ID: 16856803)
1. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.
Gabrilovich DI
Expert Opin Biol Ther; 2006 Aug; 6(8):823-32. PubMed ID: 16856803
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
3. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
4. A review of contusugene ladenovec (Advexin) p53 therapy.
Senzer N; Nemunaitis J
Curr Opin Mol Ther; 2009 Feb; 11(1):54-61. PubMed ID: 19169960
[TBL] [Abstract][Full Text] [Related]
5. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
6. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
Nemunaitis JM; Nemunaitis J
Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus p53 gene therapy.
Roth JA
Expert Opin Biol Ther; 2006 Jan; 6(1):55-61. PubMed ID: 16370914
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.
Merritt JA; Roth JA; Logothetis CJ
Semin Oncol; 2001 Oct; 28(5 Suppl 16):105-14. PubMed ID: 11706402
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
10. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
[TBL] [Abstract][Full Text] [Related]
11. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.
Sasaki R; Shirakawa T; Zhang ZJ; Tamekane A; Matsumoto A; Sugimura K; Matsuo M; Kamidono S; Gotoh A
Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1336-45. PubMed ID: 11728695
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic exploitation of the p53 pathway.
Lane DP; Lain S
Trends Mol Med; 2002; 8(4 Suppl):S38-42. PubMed ID: 11927286
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
15. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma.
Li JH; Lax SA; Kim J; Klamut H; Liu FF
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):607-16. PubMed ID: 10078646
[TBL] [Abstract][Full Text] [Related]
16. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model.
Miyake H; Hara I; Hara S; Arakawa S; Kamidono S
Urology; 2000 Aug; 56(2):332-6. PubMed ID: 10925118
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma.
Weinrib L; Li JH; Donovan J; Huang D; Liu FF
Cancer Gene Ther; 2001 May; 8(5):352-60. PubMed ID: 11477455
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
19. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer.
Pisters LL; Pettaway CA; Troncoso P; McDonnell TJ; Stephens LC; Wood CG; Do KA; Brisbay SM; Wang X; Hossan EA; Evans RB; Soto C; Jacobson MG; Parker K; Merritt JA; Steiner MS; Logothetis CJ
Clin Cancer Res; 2004 Apr; 10(8):2587-93. PubMed ID: 15102659
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line.
Qi V; Weinrib L; Ma N; Li JH; Klamut H; Liu FF
Int J Hyperthermia; 2001; 17(1):38-47. PubMed ID: 11212879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
